24.10.2013

Finland’s Turku is a centre for pharmaceutical R&D

Both large and small pharmaceutical companies based in Turku have launched new products for international markets.

The Finnish pharmaceutical company Orion is aiming to be “The Best R&D Organization in the World by 2017” and has R&D units in Turku and Espoo. The company’s pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and the Easyhaler pulmonary drugs. Orion is currently developing anti-androgens for the treatment of prostate cancer. Orion’s net sales in 2012 amounted to EUR 980 million.

Pharmaceutical giant Bayer has a factory in Turku which specializes in the development and production of high quality products for global distribution. Bayer’s hormonal contraceptive product Skyla, which was developed in Finland and launched on the American market earlier this year, will also be launched in Finland and the rest of the world in 2014 under the name Jaydess.

New products created in Turku

Turku-based Biotie, a Finnish drug development company focused primarily on products for neurodegenerative and psychiatric disorders, has developed the drug Selincro for alcohol dependency. Selincro received European marketing authorization in February 2013 and is currently being rolled out across Europe by Biotie’s partner H. Lundbeck A/S.

Faron Pharmaceutical Ltd., a clinical stage drug discovery and development company in Turku, is currently developing the first pharmacological treatment for acute respiratory distress syndrome (ARDS) as part of its Traumakine programme. The product may come on the market in 2016. Faron Pharmaceutical already has a partner in Japan and may also be looking for a partner for the European market.

Turku-based company Hormos Medical developed the drug Osphena which has been approved by the FDA in the United States for the treatment of severe dyspareunia. Hormos Medical’s R&D programmes have recently been acquired by Forendo Pharma, a new drug development company started in Turku with a focus on endometriosis and male low testosterone.

Source: Turun Sanomat, Orion, Biotie, Faron Pharmaceutical, Forendo Pharma